Larry Harshyne

Associate Professor

Thomas Jefferson University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Purpose: In locally advanced resectable squamous cell carcinoma of the head and neck (SCCHN), patients treated with neoadjuvant chemotherapy with major pathologic response (MPR) or pathologic complete response (pCR) have overall survival (OS) rates superior to those of patients with poorer pathologic responses. To improve efficacy, we added the PD-1 inhibitor nivolumab to neoadjuvant chemotherapy and evaluated the combination. Patients and Methods: In this single-arm, open-label phase II trial, patients with newly diagnosed stage III to IV human papillomavirus (HPV)–negative SCCHN in the oral cavity, oropharynx, hypopharynx, and larynx or stage II to III HPV-positive oropharyngeal SCCHN received neoadjuvant carboplatin and paclitaxel (6 weeks) plus nivolumab (every other week), followed by surgery and adjuvant radiotherapy ± chemotherapy. The primary endpoint was pCR at the primary site. Results: Thirty-four patients were enrolled and received neoadjuvant therapy. Thirty-three patients received surgery (R0 resection = 100%). Disease sites included the oral cavity (79%), oropharynx (12%), hypopharynx (6%), and larynx (3%). Twenty-eight (85%) patients had stage IVA disease. The median postsurgical follow-up was 35.3 months. Fourteen (41%) patients had grade 3/4 treatment-related adverse events. Twenty-seven (82%) patients completed all cycles of neoadjuvant therapy. Twenty-four (73%) patients had at least an MPR at the primary site, and 15 (45%) had a pCR. In an unplanned analysis at 3 years, recurrence-free survival and OS were 74% and 83%, respectively. Conclusions: This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN.

Year:

2026

Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs, offering promise to improve response rates. We leveraged multiomic data from a randomized, presurgical neoadjuvant trial (NCT03618654) evaluating a single infusion of the anti–PD-L1 ICI durvalumab with or without daily, standard dose metformin in previously untreated, nondiabetic patients with HNSCC to understand predictors of response and the effect of combination therapy. Patients and Methods: Clinical, pathologic, and correlative data were analyzed to investigate response and resistance mechanisms. We present an in-depth multiomic analysis of primary tumor specimens to study treatment response/resistance in human papillomavirus–positive HNSCC. Results: Baseline samples revealed that myofibroblastic cancer-associated fibroblast and extracellular matrix signatures were enriched in durvalumab plus metformin nonresponders, which were localized to the leading tumor edge on spatial transcriptomics. In contrast, baseline responder samples were enriched for the Langerhans-like dendritic cell (DC) state and IFN signatures. Treatment increased intratumoral CD8+ T-cell and IFN signatures and peripheral blood CCL2 levels. Responders demonstrated macrophage and DC enrichment and antigen processing and presentation upregulation. Enrichment of cell cycle–related gene sets, specifically the MYC targets V1 hallmark gene set, correlated with nonresponse. Conclusions: Early response and resistance dynamics for durvalumab plus metformin in human papillomavirus–positive HNSCC reveal baseline extracellular matrix–myofibroblastic cancer-associated fibroblast as predictive of nonresponse. In contrast, responders were distinguished by baseline enrichment in the Langerhans-like DC state and posttreatment antigen-presenting gene sets.

Year:

2025

Immune checkpoint inhibition (ICI) has emerged as a critical treatment strategy for squamous cell carcinoma of the head and neck (HNSCC) that halts the immune escape of the tumor cells. Increasing evidence suggests that the onset, progression, and lack of/no response of HNSCC to ICI are emergent properties arising from the interactions within the tumor microenvironment (TME). Deciphering how the diversity of cellular and molecular interactions leads to distinct HNSCC TME subtypes subsequently governing the ICI response remains largely unexplored. We developed a cellular-molecular model of the HNSCC TME that incorporates multiple cell types, cellular states, and transitions, and molecularly mediated paracrine interactions. Simulation across the selected parameter space of the HNSCC TME network shows that distinct mechanistic balances within the TME give rise to the five clinically observed TME subtypes such as immune/non-fibrotic, immune/fibrotic, fibrotic only and immune/fibrotic desert. We predict that the cancer-associated fibroblast, beyond a critical proliferation rate, drastically worsens the ICI response by hampering the accessibility of the CD8 + killer T cells to the tumor cells. Our analysis reveals that while an Interleukin-2 (IL-2) + ICI combination therapy may improve response in the immune desert scenario, Osteopontin (OPN) and Leukemia Inhibition Factor (LIF) knockout with ICI yields the best response in a fibro-dominated scenario. Further, we predict Interleukin-8 (IL-8), and lactate can serve as crucial biomarkers for ICI-resistant HNSCC phenotypes. Overall, we provide an integrated quantitative framework that explains a wide range of TME-mediated resistance mechanisms for HNSCC and predicts TME subtype-specific targets that can lead to an improved ICI outcome.

Year:

2025

Macrophages are highly plastic cells central to pathogen removal, tissue regeneration, and inflammation, making them key targets in biomaterial design for improved clinical outcomes. Foreign body responses (FBRs) to implanted biomaterials often involve excessive macrophage-mediated inflammation, leading to fibrotic encapsulation, infection, and implant failure. Advances in tissue engineering demonstrate that macrophage polarization - the transition from pro-inflammatory M1 to anti-inflammatory M2 phenotypes - can be influenced by biomaterial properties to mitigate these responses and enhance regeneration. This review synthesizes the relationship between biomaterial properties, such as surface chemistry, structure, and stiffness, and their ability to modulate macrophage behavior. Key innovations, including tailored scaffold architectures, bioactive coatings, and cytokine delivery systems, have shown promise in guiding macrophage polarization for improved bone, soft tissue, and head and neck reconstruction outcomes. Strategies like hydrogels and nanostructured materials enable spatially and temporally controlled macrophage modulation, mimicking native extracellular matrix dynamics, mitigating chronic inflammation, and accelerating vascularization, extracellular matrix remodeling, and tissue integration. By integrating recent findings, this review provides a framework for designing biomaterials that actively modulate macrophage activity to overcome FBR and enhance healing. It identifies critical gaps, such as understanding macrophage-stromal interactions, developing personalized biomaterial designs to address patient variability, and leveraging advanced technologies like artificial intelligence in scaffold optimization. These insights advance the development of biomaterials that restore tissue function and address unmet clinical needs in regenerative medicine.

Year:

2025

Figure s4. Gene set enrichment analysis (GSEA) across baseline responder vs. nonresponder comparisons and baseline vs. post-treatment analyses in the durvalumab-metformin clinical trial and other clinical trial cohorts. GSEA was performed to assess differences between baseline responders and nonresponders, as well as baseline vs. post-treatment samples

Year:

2025

Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs, offering promise to improve response rates. We leveraged multiomic data from a randomized, presurgical neoadjuvant trial (NCT03618654) evaluating a single infusion of the anti–PD-L1 ICI durvalumab with or without daily, standard dose metformin in previously untreated, nondiabetic patients with HNSCC to understand predictors of response and the effect of combination therapy. Patients and Methods: Clinical, pathologic, and correlative data were analyzed to investigate response and resistance mechanisms. We present an in-depth multiomic analysis of primary tumor specimens to study treatment response/resistance in human papillomavirus–positive HNSCC. Results: Baseline samples revealed that myofibroblastic cancer-associated fibroblast and extracellular matrix signatures were enriched in durvalumab plus metformin nonresponders, which were localized to the leading tumor edge on spatial transcriptomics. In contrast, baseline responder samples were enriched for the Langerhans-like dendritic cell (DC) state and IFN signatures. Treatment increased intratumoral CD8 + T-cell and IFN signatures and peripheral blood CCL2 levels. Responders demonstrated macrophage and DC enrichment and antigen processing and presentation upregulation. Enrichment of cell cycle–related gene sets, specifically the MYC targets V1 hallmark gene set, correlated with nonresponse. Conclusions: Early response and resistance dynamics for durvalumab plus metformin in human papillomavirus–positive HNSCC reveal baseline extracellular matrix–myofibroblastic cancer-associated fibroblast as predictive of nonresponse. In contrast, responders were distinguished by baseline enrichment in the Langerhans-like DC state and posttreatment antigen-presenting gene sets.

Year:

2025

Figure s5. Baseline immune cell composition in responders and nonresponders across bulk, tumor, and stromal compartments & Immune cell deconvolution analysis in bulk tumor samples of responders and nonresponders before and after durvalumab-metformin treatment.

Year:

2025

Figure s11. Carcinoma ecotype differences at baseline and after treatment in HPV+ HNSCC responders and non-responders. This figure illustrates differences in carcinoma ecotype composition before and after treatment in HPV+ HNSCC patients

Year:

2025

Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary site alone. ‘Overall path response’ refers to analysis based on primary + lymph node response.

Year:

2025

Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Collaborators (22)

Andrew South

Oros Family Professor in Rare Skin Diseases

University of Wisconsin-Madison

UNITED STATES
View details

Megan Roche

Thomas Jefferson University

UNITED STATES
View details

Ramkrishna Mitra

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details

Nolan B. Seim

Assistant Professor

Ohio State University

UNITED STATES
View details

David Cognetti

department of surgery thomas jefferson university hospital sidney kimmel medical college philadelphia university and tho

UNITED STATES
View details

Joseph Curry

Associate Professor

Thomas Jefferson University Hospital

UNITED STATES
View details

Douglas Hooper

Thomas Jefferson University

UNITED STATES
View details

Tingting Zhan

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Rita Axelrod

Professor

Thomas Jefferson University

UNITED STATES
View details

George Prendergast

Professor, President & CEO

Lankenau Institute for Medical Research

UNITED STATES
View details

Hushan Yang

Professor

Thomas Jefferson University

UNITED STATES
View details

Benjamin Leiby

Professor

Thomas Jefferson University

UNITED STATES
View details

Charalambos Solomides

Professor

Thomas Jefferson University

UNITED STATES
View details

Rajanikanth Vadigepalli

Thomas Jefferson University

UNITED STATES
View details

Scott W. Keith

Thomas Jefferson University

UNITED STATES
View details

Lawrence C. Kenyon

Cooper University Hospital

UNITED STATES
View details

Jennifer M. Johnson

Thomas Jefferson University

UNITED STATES
View details

John R. Eisenbrey

Thomas Jefferson University

UNITED STATES
View details

Ubaldo Martinez-Outschoorn

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Stacey Gargano

Thomas Jefferson University Hospital

UNITED STATES
View details

Ralph Zinner

Professor

University of Kentucky

UNITED STATES
View details

Adam J. Luginbuhl

-

UNITED STATES
View details